Line 1: | Line 1: | ||
{{Aix-Marseille|title=Human Practices|toc=__TOC__}} | {{Aix-Marseille|title=Human Practices|toc=__TOC__}} | ||
− | [[ | + | We have thought about the Human Practices since the very beginning of [[Team:Aix-Marseille/Project|'''KILL XYL''']]. We had drawn the limits of it and found out which actors were going to be involved before deciding our scientific approach. This way our project could be as adapted as possible to the factual needs of society. |
− | + | Then, the more our [[Team:Aix-Marseille/Project|project]] advanced and defined itself, the more we worked on the practical side of Human Practices. | |
− | + | To integrate the farmer’s opinion, we contacted them and did [[Team:Aix-Marseille/HP/Surveys|surveys]], first via the web and then in person, during events around agriculture LIEN. This approach helped us to figure out their needs and their thoughts, about [[Team:Aix-Marseille/Xylella_fastidiosa|''Xylella fastidiosa'']] and the communication around it. | |
− | + | We got [[Team:Aix-Marseille/HP/Interviews|advices]] from different experts : Mireille Ansaldi, the research director of the phage cycle and bacteria metabolism in LCB CNRS ; Marie-Agnès Jacques, INRA’s researcher specialised in [[Team:Aix-Marseille/Xylella_fastidiosa|''X. fastidiosa'']], and Jacques Van Helden, professor in Aix-Marseille University in bioinformatics, genome analysis, and more specifically analyses of regulatory sequences. | |
+ | Finally, in order to get advice on the relevance of our project we contacted Ms. Jacques, a [[Team:Aix-Marseille/Xylella_fastidiosa|''X. fastidiosa'']] specialist from the Institut National de la Recherche Agronomique(INRA). She beware us that we would be defined by the legislation as a GMO product. We then began a complete study of [[Team:Aix-Marseille/Legislation|french’s and European's law]], thank to a collaboration with the [https://2017.igem.org/Team:Evry_Paris-Saclay Evry Paris-Saclay] team to see if we will be able to sell our product in France and in Europe. | ||
− | + | To sum up, our project grew entwined with the human practices. | |
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + |
Revision as of 15:21, 24 October 2017
Human Practices
We have thought about the Human Practices since the very beginning of KILL XYL. We had drawn the limits of it and found out which actors were going to be involved before deciding our scientific approach. This way our project could be as adapted as possible to the factual needs of society.
Then, the more our project advanced and defined itself, the more we worked on the practical side of Human Practices.
To integrate the farmer’s opinion, we contacted them and did surveys, first via the web and then in person, during events around agriculture LIEN. This approach helped us to figure out their needs and their thoughts, about Xylella fastidiosa and the communication around it.
We got advices from different experts : Mireille Ansaldi, the research director of the phage cycle and bacteria metabolism in LCB CNRS ; Marie-Agnès Jacques, INRA’s researcher specialised in X. fastidiosa, and Jacques Van Helden, professor in Aix-Marseille University in bioinformatics, genome analysis, and more specifically analyses of regulatory sequences.
Finally, in order to get advice on the relevance of our project we contacted Ms. Jacques, a X. fastidiosa specialist from the Institut National de la Recherche Agronomique(INRA). She beware us that we would be defined by the legislation as a GMO product. We then began a complete study of french’s and European's law, thank to a collaboration with the Evry Paris-Saclay team to see if we will be able to sell our product in France and in Europe.
To sum up, our project grew entwined with the human practices.